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ABSTRACT 
Aberrant Ras signalling drives 30% of cancers and 
inhibition of Rho family small-GTPase signalling 
has been shown to combat Ras-driven cancers. 
Here we present the discovery of a 16mer cyclic 
peptide that binds to Cdc42 with nanomolar 
affinity. Affinity maturation of this sequence has 
produced a panel of derived candidates with 
increased affinity and modulated specificity for 
other closely related small-GTPases. The structure 
of the tightest binding peptide was solved by NMR 
and its binding site on Cdc42 determined. 
Addition of a cell penetrating sequence allowed  
 
 
 
 
the peptides to access the cell interior and engage 
with their target(s), modulating signalling 
pathways. In Ras-driven cancer cell models, the 
peptides have an inhibitory effect on proliferation 
and show suppression of both invasion and 
motility. As such they represent promising 
candidates for Rho-family small GTPase inhibitors 
and therapeutics targeting Ras-driven cancers. Our 
data adds to the growing literature demonstrating 
that peptides are establishing their place in the 
biologics arm of drug discovery. 
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Aberrant signalling from the small G protein Ras 
has been shown to drive approximately one third 
of all human cancers making it a compelling 
therapeutic target (1). Targeting Ras isoforms 
directly has proven difficult historically, although 
some progress has been made recently (2-4). 
Cdc42, together with Rac1, RhoA and other 
members of the Rho family small GTPases, is a 
key regulator of the actin cytoskeleton and 
therefore cell architecture and motility (reviewed 
in (5)). Cdc42 is often found to signal downstream 
of the master regulator, Ras, and induces the 
formation of filopodia by initiating actin 
remodeling, which is key to cell motility. 
Deregulation of Cdc42, therefore, results in the 
progression of several disease states, including 
tumour metastasis (6). Genetic deletion of Cdc42 
in Ha-Ras G12V-transformed fibroblasts results in 
a significant block in cell cycle progression and 
therefore in cell proliferation, demonstrating an 
essential role of Cdc42 in Ras-induced 
transformation (7). Correspondingly, 
overexpression of Cdc42 is implicated in several 
human cancers where it correlates with poor 
prognosis (8-10). Although mutations in Cdc42 
are rarely found in human cancers, oncogenic 
mutations have been extensively characterized in 
its regulators e.g. the GEFs Dbl (11) and Asef2 
(12) and the GAP, DLC1 (13). Cdc42 participates 
in both physiological and tumorigenic processes 
by interacting with its effector proteins. One such 
family of effectors, the CRIB proteins, includes 
activated Cdc42-associated kinase (ACK), the p21 
activated kinases (PAKs) and Wiskott-Aldrich 
syndrome proteins (WASPs)(14). 
 
Inhibition of Cdc42 has been demonstrated to 
reverse the oncogenic properties of v-Ha-Ras 
transformed cells in experiments employing the 42 
amino acid G protein binding region (GBD) of 
ACK, a previously mentioned Cdc42 effector (15). 
This peptide binds to Cdc42 at a binding surface 
which prevents it interacting with its downstream 
effector proteins, all of which employ overlapping 
binding surfaces on Cdc42 (16). This inhibits 
Cdc42-driven signalling pathways, which must be 
necessary for transformation by Ras in this model.  
 
This observation, together with our structural and 
biophysical analysis of the Cdc42-ACK GBD 
complex (17,18) prompted us to undertake a 
peptide discovery campaign, using CIS display 
technology, to identify a Cdc42 binding peptide 
that would similarly inhibit effector interaction 
and Ras-driven oncogenesis but would possess 
properties more compatible with future use as a 
lead therapeutic. CIS display is a biological 
display technology that links the DNA coding 
sequence of library members directly to the 
encoded peptide in a cell-free system by 
employing the binding properties of the R1 RepA 
protein to the origin of replication i.e. the cis-
binding activity of the protein to its coding DNA 
(19). The technology allows generation and 
interrogation of the very large library sizes 
(routinely 1013 library members) associated with 
cell-free display and offers greater stability than 
many orthogonal methods (for example ribosome 
or RNA display) by employing DNA and the 
robust CIS RepA system. 
 
Despite the knowledge for over 30 years that 
targeting Ras and other small G proteins would 
have enormous therapeutic potential, multiple 
issues have been encountered in attempts to attack 
them (20). Small G-proteins all contain a 
conserved G domain comprising five α helices 
surrounding a six-stranded β sheet (21) This 
architecture mediates binding to Mg2+ and either 
GTP or GDP, with GTP binding associated with 
activation. The picomolar affinity for guanine 
nucleotides together with the ubiquitous nature of 
guanine nucleotide usage and cellular abundance 
has prevented the development of small molecule 
therapeutics based on inhibition of nucleotide 
binding (22). Likewise the relatively smooth 
surface of the small G proteins has also 
confounded searches for small molecule 
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therapeutics due to the lack of other binding 
pockets, although some progress has been made in 
this regard in recent years (23).	
 
Peptides and their orthologues can bind surfaces of 
proteins inhospitable to small molecules and as 
such can inhibit protein-protein interactions 
successfully, with the added property of exquisite 
specificity. Thus, peptides or peptidomimetics 
provide an opportunity to mimic the effect of ACK 
GBD overexpression, which was effective in 
inhibiting transformation in oncogenic NIH3T3 
cells (15) by allowing targeting of the functional 
face of the Cdc42. Peptide therapeutic candidates 
have traditionally suffered from poor delivery and 
stability, however progress on both fronts 
continues to be made, using cell penetrating 
peptides (CPPs)(24) and delivery vehicles (25) and 
introducing unnatural modifications into peptide 
structures (26-29), allowing peptide biologics to 
join the current repertoire of therapeutics (30). 
 
Here we report the identification and maturation of 
a lead 16mer cyclic peptide using CIS display (19) 
to produce a panel of cyclic peptides that bind 
Cdc42 with low nanomolar affinity. Binding has 
been characterized by biophysical methods, 
indicating the docking site on Cdc42 and 
demonstrating varying selectivity between 
peptides and related small GTPases. The peptides 
are shown to have promising phenotypic effects in 
cells when linked to a nona-arginine motif 
facilitating entry; reducing proliferation and 
particularly inhibiting motility and invasion. These 
peptides provide a promising lead platform for 
development of a therapeutic peptidomimetic 
targeting Rho-family signalling and therefore 
preventing oncogenesis in Ras-driven cancers. 
 
Results 
 
CIS display biopanning 
Selections were performed following the work 
plan detailed in (19). Ten naïve peptide libraries, 
encoding peptides 10-25 amino acids long were 
separated into three pools: short linear (SL) (10 
and 12mer), long linear (LL) (16, 20 and 25mer) 
and cyclic (C) (14, 15, 16, 17 and 18mer) and 
selected against Cdc42·GMPPNP. The five 
libraries in the cyclic pool contained two constant 
cysteines (at positions N+4 and C-4) designed to 
allow production of disulphide-linked cyclic 
peptides under non-reducing conditions. Two 
methods of elution were used in parallel for each 
library pool: heating to 75˚ C or competition with 
the ACK GBD peptide, generating six individual 
selections. Competition with the ACK GBD was 
designed to select for peptides that bind to an 
interface on Cdc42 that overlaps with that of ACK. 
After four rounds of biopanning DNA recovery 
significantly increased (data not shown), 
indicating binding peptide enrichment. Next 
generation sequence analysis of the peptide coding 
DNA indicated three highly enriched peptides 
(which each represented over 20% of recovered 
sequences), two from the short linear and one from 
the cyclic library pools, as shown in Figure 1A. 
The three selection pools showed different patterns 
of enrichment. In the long linear libraries 
individual sequences are hydrophobic, suggestive 
of less specific binders, with no dominant motif. In 
contrast the short linear pool produced a highly 
dominant motif (HISWPXN) in both heat and 
competitive elution experiments while in the 
cyclic libraries one sequence (C1) was strongly 
enriched, especially under competitive elution 
conditions where it comprised ~70% of the 
recovered sequences. Several of the more 
frequently occurring alternative sequences selected 
from the short linear and cyclic libraries were 
single site variants stemming from the dominant 
sequence. No strong homology was shared across 
the cyclic and short linear consensus sequences.	
 
Peptide validation 
Phage display of the three most highly selected 
sequences was used to validate peptide specificity 
for Cdc42 in an ELISA assay, as well as testing the 
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nucleotide dependence of the interaction. Results 
for the three dominant sequences, C1, SL1 and 
SL2, are shown in Figure 1B. SL2 bound strongly 
but non-specifically to all the proteins tested, 
including the negative control, BSA. SL1 gave 
weaker signals, which were again non-specific. C1 
however generated strong signals with 
Cdc42·GMPPNP and low signals with 
Cdc42·GDP, RalB·GMPPNP and BSA. Some 
binding between C1 and Rac1·GMPPNNP was 
also observed. These data suggested that, among 
these targets, C1 was specific for 
Cdc42·GMPPNP. 
 
Quantitative peptide binding affinities were next 
determined by competition with the Cdc42-ACK 
GBD complex in scintillation proximity assays 
(SPAs). Peptide solubility at pH7.5 (<200 μM) 
tended to limit the concentration in the assays, 
such that the SL1 and SL2 peptides did not 
produce full competition data and could not be 
fitted (data not shown). C1 however, inhibited the 
Cdc42·GMPPNP-ACK GBD interaction with a Kd 
of 350nM (Figure 1C). The competition observed 
did not go to completion, i.e. the signal due to 
Cdc42-ACK GBD did not reach zero, suggesting 
that the binding site for C1 on Cdc42 partially 
overlaps with the ACK-Cdc42 interaction surface. 
Interestingly the affinity of C1 for 
Cdc42·GMPPNP was also shown to be dependent 
on the disulphide bond in the cyclic peptide, since 
addition of 50mM DTT or mutation of the cysteine 
residues to serine lowered the binding affinity 
significantly (Figure 1C). 
 
C1 validation in cells 
The C1 sequence was re-synthesized with the 
addition of a C-terminal nona-arginine motif (9R) 
to facilitate cell penetration and an N-terminal 
linked FAM (carboxyfluorescein) group for 
visualization. The binding of this modified peptide 
to Cdc42 was confirmed by fluorescence 
polarization (FP) and the results are shown in 
Figure 2A.  Direct binding of Cdc42·GMPPNP to 
the FAM-C1-9R peptide gave a dissociation 
constant of 0.36 ± 0.09 µM (upper panel). The 
binding of FAM-9R was so low it could not be 
accurately determined. The Kd of untagged C1 for 
Cdc42·GMPPNP in competition FP was 
determined to be 1.61 ± 0.44 µM (Figure 2A, 
lower panel), indicating that the addition of 9R 
and FAM did not adversely affect Cdc42 binding 
in vitro. The very low affinity of FAM-9R for 
Cdc42 suggest that the slight difference in affinity 
between FAM-C1-9R and C1 may just reflect 
technical differences in the experimental 
methodologies. 
 
To assess peptide entry into cells, mouse embryo 
fibroblasts (MEFs), were incubated in media 
containing FAM-C1-9R at concentrations from 60 
nM to 10 µM for between 2 and 5 hours at 37 ºC 
before being washed and imaged by live cell 
confocal microscopy. Figure 2B shows images of 
cells exposed to 10 µM peptide compared with a 5 
µM peptide treatment and a FITC control. At 
peptide concentrations of 10 µM the MEFs showed	 signs	 of	 membrane	 disruption	 and	 cell	death. Neither the 5µM peptide or the FITC-
treated cells show such atypical cells at the time-
points observed. This data corroborates previous 
observations of a toxicity threshold for the nona-
arginine CPP (31) and therefore 5 µM FAM-C1-
9R was the maximum concentration used in 
subsequent experiments. Example images for 
treatments with ≤ 5 µM peptide in Figure 2C show 
that the peptide can access the cell interior at a 
variety of concentrations and within 2 hours of 
dosing. The cells in these images appear healthy 
with the majority of the peptide dispersed in a 
punctate pattern in the cytoplasm, suggesting an 
endosomal location, as is often seen with peptides 
(32,33). The cytosol and nuclei of the cells 
however, show fluorescence above background 
levels, suggesting that not all peptide is confined 
to endosomes and that endosomal exit has allowed 
a wider distribution in the cells.  
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  Next we investigated the effects of FAM-C1-9R 
on relevant cell signalling pathways. As our 
ultimate aim was to engineer peptide inhibitors of 
Cdc42 in order to attack Ras-driven cancers, we 
chose to examine signalling pathways using MEFs 
derived from four mice, two of which carried a 
Cre-induced G12D oncogenic K-Ras mutant (34). 
Previous work in our laboratory (our unpublished 
results) and from others (35,36) has shown Stat3 
Tyr705 is a target for phosphorylation downstream 
of ACK, so pTyr705 Stat3 was chosen as a readout 
for an active Cdc42-ACK signalling pathway. 
Cells were treated with 1 µM FAM-C1-9R for 1 
and 24 hours alongside untreated controls. Four 
different MEF isolates were used from four 
littermates: A and C expressing G12D K-Ras, B 
and D expressing wild-type K-Ras. Figure 2D 
shows pTyr705 Stat3 levels demonstrating a 
marked decrease at one hour in cell lines A, B and 
D, returning to untreated levels by the 24 hour 
time-point, while total Stat3 remained relatively 
constant, demonstrating a reduction in signalling 
by Cdc42 on exposure to FAM-C1-9R. ERK 
phosphorylation was also probed, to assess activity 
through the MAPK pathway and results are shown 
in Figure 2D. MEK induces phosphorylation of 
ERK1/2 at residues threonine 202 and tyrosine 
204, so levels of pThr202/pTyr204 ERK1/2 were 
analysed. Suppression of pThr202/pTyr204 
ERK1/2 phosphorylation is visible at 1 hour for 
cells lines A and B, although not in cell lines C and 
D, suggesting that the MAPK pathway, 
downstream of Ras, can be affected by FAM-C1-
9R.  
 
Taken together, these data demonstrate that FAM-
C1-R9 enters cells, likely by an endosomal route 
but can escape into other parts of the cell, where it 
is able to elicit the signalling effects that it was 
designed to accomplish. 
 
 
Maturation of C1 
Although CIS display offers the potential to 
interrogate some of the largest naïve sequence 
space available, the naïve 16mer library used in 
the original selections covers only approximately 
0.0125% of possible sequences, suggesting the 
likelihood that other potentially higher affinity 
sequences could exist that had not been available 
for selection. Thus a maturation library designed 
to search the sample space around the C1 sequence 
was constructed and selected against 
Cdc42·GMPPNP. Sequence analysis of the 
selected peptides, after 4 rounds of biopanning, 
showed that residue replacement was favoured at 6 
positions whereas 3 other positions saw no 
substitutions highlighting their possible key roles 
in the target engagement. The fold enhancement of 
individual amino acids at these positions compared 
to the initial library are shown in Figure 3A. A 
panel of peptides was then synthesized, based on 
the enriched sequences observed in the NGS 
analysis of the selections, to represent the most 
favourable residue replacements, as shown in 
Figure 3B. Binding affinities for this panel of 
peptides were determined by competition SPA, as 
described above and dissociation constants are 
listed in Figure 3B with representative data shown 
in Figure 3C. For five of these second generation 
peptides, the affinity for Cdc42 was increased 
significantly (5-20-fold) and reached values close 
to the affinity of the complete ACK GBD for 
Cdc42 (20-30 nM), lending further promise for 
their ability to act as competitive inhibitors of 
Cdc42 effector proteins in cells.  
 
The maturation data suggest that the combined 
H8R, G10D substitutions in peptide candidates are 
important for increasing binding affinity, as all 
peptides with these substitutions have an affinity 
of 32 nM or lower for Cdc42. Effects of other 
replacements are less clear, however the combined 
effect of P1T, H8Q and Q16R are favourable in P1 
and P9.  
 
Mode of peptide binding to Cdc42 
One of the second generation peptides with the 
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tightest binding, P7, was chosen for structural 
analysis by NMR. 15N-HSQC spectra of Cdc42 
were recorded and the chemical shifts of the 
backbone amides were monitored with increasing 
P7 peptide concentrations (Figure 4A). Most of the 
peaks in the Cdc42 spectrum that experienced 
chemical shift changes were in slow exchange, so 
that peaks corresponding to both the free and 
bound species were observable in the intermediate 
timepoints of the titration. Residues, whose peaks 
in the complex spectrum could be assigned and 
whose chemical shift changes were higher than 
average, were identified (Supplementary Figure 
1). To these were added those residues whose 
peaks had moved too far from their position in the 
free Cdc42 spectrum to be reliably assigned 
(labelled in blue in Figure 4A). The residues with 
significant shift changes and which are solvent 
accessible are shown mapped onto the Cdc42 
structure in Figure 4B. Chemical shift 
perturbations can indicate that a particular residue 
is involved in the interface with the binding 
partner, but may also be due to longer-range 
allosteric effects.  Residues that are not accessible 
to the solvent are unlikely to be involved in direct 
interactions and their removal reduces the number 
of indirect contributions to chemical shift 
mapping. The chemical shift mapping localizes the 
P7 binding site to a face of Cdc42 that is involved 
in binding to a critical section of the N-termini of 
the GBDs of effector proteins (18,37).  
 
The structure of the P7 peptide in isolation was 
determined by NMR. The peptide was fully 
assigned using standard homonuclear experiments 
and the NOESY was used to generate 440 unique 
distance restraints. The RMSD of the final, water-
refined structures is 0.37Å over all backbone 
atoms and the large number of distance restraints 
mean that the structure is well defined (Table 1). 
The disulphide bond, in combination with the 
presence of two proline residues within the middle 
of sequence, which lend rigidity, means that the 
peptide adopts a tightly constrained structure 
(Figure 4C and D). Stacking interactions between 
the three aromatic residues within the sequence 
(Trp11, Trp14, Tyr15) further stabilize the 
structure. There is no regular secondary structure 
in the peptide, which merely forms a series of 
turns. The overall structure forms a single turn of a 
loose, irregular, left-handed helix between residues 
3 and 15, pinned by the disulphide bond between 
Cys4 and Cys13, with the N- and C-termini 
protruding out on opposite sides (Figure 4C). Arg8 
and Asp10, which drive higher binding affinities, 
are displayed on a loop opposite the disulphide 
bind, which presumably constitutes the Cdc42 
binding face. (Figure 4D) The structure explains 
why the disulphide bond is necessary for high 
affinity binding to Cdc42, since there is only one 
residue, Val6, in its hydrophobic core (Figure 4C). 
Without the disulphide, therefore, this compact 
structure would not form stably and would be 
unable to display the Cdc42 binding face correctly. 
 
Data-driven docking (HADDOCK) was next used 
to predict the structure of the Cdc42-P7 complex 
(38,39). The NMR chemical shift mapping was 
used to determine the active residues in Cdc42 and 
the matured peptide sequences and affinity 
measurements (Figure 3B) were used to determine 
the active residues in the peptide (Arg8 and 
Asp10). The complete Cdc42-P7 docked model is 
shown in Figure 5A and B and identifies both 
hydrophobic and polar interactions between Cdc42 
and P7. In particular, the conserved peptide 
residues Trp11 and Tyr15 (found in all second 
generation peptides except P9) form the 
hydrophobic core of interactions with a Cdc42 
pocket between strand β1 and helices α1 and α5. 
This pocket is lined by Cdc42 residues such as 
Val42, Val44 and Tyr23. Tyr15 is also close to 
Cdc42 residues Thr25 and Asn26, which could 
make polar interactions with the Tyr OH group. 
Arg8 and Asp10 are predicted to form a salt bridge 
with each other in the free peptides but Asp10 is 
within 3 Å of Lys166Cdc42 in the model and hence 
may form a salt bridge. Arg8 is within 3 Å of 
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Tyr23Cdc42 and potentially could form a hydrogen 
bond (Figure 5C), although the backbone amide of 
Tyr23Cdc42 did not show chemical shift changes 
when the peptide bound. The Cdc42 pocket that 
binds to P7 also contacts the N-terminus of the 
ACK GBD in the Cdc42-ACK complex (Figure 
6). This is consistent with the previous observation 
that P7 can compete with ACK GBD binding to 
Cdc42 (Figure 1C), which implies overlapping 
binding sites. Importantly this region of Cdc42 
contributes significantly thermodynamically to the 
binding of both ACK and WASP (18,37) and is 
also demonstrated to bind the other known CRIB 
effectors PAK1 and Par6 where structural 
information is available (Figure 6), suggesting that 
P7 will disrupt binding to these proteins as well. 
 
Second generation peptide specificity and 
cellular target engagement 
The two tightest binding second generation 
peptides, P1 and P7, were next synthesized with 
FAM and 9R additions for use in cell assays. The 
tagged proteins were first tested for their ability to 
bind Cdc42. As the specificity of the interaction of 
these peptides is likely to be paramount for any 
future therapeutic, a survey of the binding 
affinities of these peptides across a wider panel of 
small GTPases was also undertaken. The panel of 
small G proteins tested included both Cdc42·GDP 
and Cdc42·GMPPNP along with the classic Rho-
family exemplars, Rac1 and RhoA. We also 
included members of the Ras family: K-Ras and 
RalA as examples of more diverse small G 
proteins. Binding of tagged C1, P1 and P7 with the 
selected small G proteins was assessed using FP. 
The results are shown in a radar plot in Figure 7 
and are tabulated in Table 2. All three peptides 
have relatively weak affinity for K-Ras and RalA 
as expected. The data demonstrate that overall P7 
has higher specificity than C1 or P1, showing 
considerably tighter binding to Cdc42 and Rac1 
than other small-GTPases. P1 and C1 have more 
similar specificity profiles and bind RhoA with 
comparable affinity to Cdc42 and K-Ras to a 
lesser extent. All three peptides however show 
only marginally better binding to Cdc42·GMPPNP 
than Cdc42·GDP. 	
 
Cellular entry of these second generation peptides 
was demonstrated by confocal microscopy using 
A549 cells. The A549 cell line is a human lung 
epithelial cell line, which is homozygous for K-
Ras G12S. As such it is a good representative of 
the type of cells in which these peptides would 
need to be active therapeutically. The images in 
Figure 8A show representative examples of cells 
treated with C1, P1 and P7 at varying time points 
after addition. The peptides concentrate at the 
periphery of cells in vesicular structures at 1 hour 
time points but are able to access the interior of the 
cell and appears to be distributed in the cytosol 
rather than concentrated, potentially in endosomes, 
after 3-6 h, in contrast to the previous studies 
using MEFs. 
 
The efficacy of the peptides in inhibiting the 
interaction of Cdc42 with its effector proteins was 
next tested using GST-effector domain pulldown 
inhibition assays in cell lysate. Increasing 
concentrations of unconjugated C1, P1 and P7 
were introduced into A549 cell lysate and the 
ability of Cdc42 to interact with the effector 
binding domains assessed. The data in Figure 8B 
(upper panels) show the inhibition of the 
endogenous Cdc42 interaction with immobilised 
GST-WASP GBD by peptides C1, P1 and P7 
(experiments were also performed with ACK GBD 
showing similar inhibition, data not shown). These 
data suggest that the binding of the peptides to 
Cdc42 is sufficiently stringent to inhibit Cdc42-
effector interactions amongst the myriad of 
proteins in cell lysate.  
 
These experiments were repeated with FAM-9R 
conjugated peptides to determine if these additions 
affected targeting of Cdc42 in cell lysates. These 
data were quantified and are shown, together with 
the data from the unconjugated peptides, in the 
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graph in Figure 8B (lower panel). The data shows 
that the FAM-9R conjugated peptides inhibited the 
Cdc42-WASP interaction but a considerably 
higher concentration was needed to achieve this 
than with the unconjugated peptides. The IC50s 
calculated from these data suggest that, in fact, the 
addition of FAM-9R to the peptides results in a 
>10X decrease in efficacy in cell lysates. For 
example IC50 C1 is 190nM ± 62 nM but for FAM-
C1-9R is 2200 ± 740 nM. For P7 the effect is even 
greater with the IC50 P7 calculated as 1.2 ± 0.28 
nM but for FAM-P7-9R being 65 ± 12 nM. 
Importantly these data suggest that any cellular 
effects seen with the peptides will be greatly 
enhanced when using an alternative delivery 
system and/or without the reporter group. 
 
Peptide binding to Cdc42 in vitro was further 
demonstrated using cellular thermal shift assays 
(CETSAs)(40). These assays monitor protein 
stability during thermal denaturation in cells or in 
lysate, in the presence of potential binding partners 
or inhibitors. Changes in thermal stability are 
taken as an indication of protein engagement by 
the peptides. Cdc42 levels were monitored under 
appropriate conditions in A549 cell lysates, with 
the addition of increasing concentrations of 
peptide P7 and the results are shown in Figure 8C. 
Cdc42 in lysates is destabilized in the presence of 
P7, indicating target engagement by the peptide. 
These experiments were repeated in A549 cells 
with peptide P7 added in to the cell growth media 
and allowed to enter cells for 3.5 hours (Figure 
8D). The results show a similar destabilization 
pattern of Cdc42 when the cells are exposed to 
peptide. Interestingly, at higher peptide 
concentrations (3-6 µM), which are toxic to cells, 
a rise in Cdc42 levels was noticed which then 
similarly decreased with concentration, potentially 
implying a different transport mechanism takes 
over that does not allow similar levels of target 
engagement. 	
 
 
The second generation peptides significantly 
inhibit transformation phenotypes in A549 cells 
As the peptides were able to enter cells and engage 
with Cdc42, the effects of the peptides on cellular 
properties associated with transformation were 
assessed.  Firstly proliferation was measured. The 
longevity of either the peptide sequences 
themselves or the disulphide bond was unknown 
in cells, however as the experiments in MEFs 
(Figure 2D) showed signalling restoration with 
time, the peptides were redosed at 24 hours, and 
48 hours was used as an upper time limit in 
proliferation experiments. After 48 hours 
incubation, cells treated with a 1 μM dose of the 
peptides showed significantly lower proliferation 
levels compared to the 9R control, as shown in 
Figure 9A. The most pronounced effect was seen 
for P1, while C1 and P7 show similar but slightly 
reduced potency.  At 5μM doses, greater inhibition 
of proliferation is seen, with a similar pattern of 
peptide efficacy. Overall, for all three peptides, 
C1, P1 and P7, statistically	 there	 is	 a	 significant	linear	 trend	 both	 with	 increasing	 dose	 and	increasing	 time	of	 incubation (using general linear 
models in R, data not shown), while this is not 
seen for 9R, further demonstrating biological 
activity for these peptides.	
 
Cdc42 and other Rho family small G-proteins are 
traditionally associated with cytoskeletal 
rearrangements, which govern cell motility (41). 
High migration and motility are also associated 
with aggressive oncogenic phenotypes and 
inhibition of this would therefore be highly 
desirable. It was notable from the proliferation 
assays that the 9R CPP alone begins to have a 
significant effect on cell proliferation at 
concentrations above 5 µM and as such peptides 
were only dosed at 1 µM in subsequent 
experiments. Peptides were first assessed in 
Boyden chamber assays monitoring invasion and 
migration towards higher serum concentrations 
and the results are shown in Figure 9B.  Potent 
effects for the peptides dosed at 1 μM were 
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observed. The data also show significant inhibition 
of invasion and migration by the 9R control 
(~65%), however the peptide-9R conjugates 
showed greater inhibitory effects, in particular P1 
and P7 which reduce invasion and migration by 
around 90% and 85% respectively.  
 
Next, wound healing assays were used to monitor 
co-ordinated cell motility and proliferation. A549 
cells were treated with 1 μM FAM-peptides-9R 
and monitored for 48 h. Representative images and 
data plots are shown in Figure 9C. All peptides 
showed significant inhibitory effects on wound 
closure; in the case of P1 and P7, the scratch area 
did not close within the duration of the assay. In 
contrast to the Boyden chamber assays no 
inhibitory effect was noted for 9R alone. 
 
Taken together these data suggest that the high 
affinity Cdc42 binding peptides developed here 
have the hallmarks of early lead molecules for 
therapeutic intervention in Ras-driven cancers. 
 
Discussion 
The isolation and maturation of a peptide, C1, 
capable of binding Cdc42 with mid nM affinity, 
from the naïve libraries used in the original display 
experiments described here, validates CIS display 
as a robust technique for isolating small G protein 
binding peptides. Molecular display methods all 
have to rely on the chance sampling of library 
members to some extent, as seldom, even with 
larger libraries, can all sequence space be covered 
for peptides beyond 10 residues in length. 
However, as a wholly acellular technology, CIS 
display, with larger, stable libraries, is likely to 
sample greater sequence space and thus allow the 
identification of tighter binding peptides. 
Subsequent maturation of C1 increased both the 
specificity and affinity of this peptide further, with 
the best second generation binders containing 2-4 
mutations at 6 positions and possessing ~17-fold 
increased binding to their primary target, 
Cdc42·GTP. Whilst the use of a randomly doped 
maturation library has identified 6 positions as 
being important for the improvement of binding 
efficiency, display of this library may still not 
have allowed sampling of all the most beneficial 
combinations of mutant residues. Further affinity 
maturation may be possible by using mutagenesis 
directed to these 6 positions particularly if 
harnessed with competitive regimes of selection. 
Alternatively, a rational design approach and the 
incorporation of unnatural amino acids may offer 
further scope for improved affinities. 
Closer investigation of C1 and its derivatives has 
demonstrated that the specificity for active Cdc42 
was not as high as initially indicated (see Figure 
1B vs. Figure 7) with the peptides binding closely 
related small GTPases. Binding to Cdc42 is also 
insensitive to the nucleotide state, thus the 
peptides may also interfere with Cdc42 
interactions when inactive. Peptide maturation has 
however resulted in tighter Cdc42 binding and 
also modulation of Rho family specificity. P7 in 
particular shows improved targeting of Rac1 and 
Cdc42 over other Rho family proteins and K-Ras.  
 
In general, tighter binding to a target does 
correlate with increased specificity. This holds true 
for general off-target binding events, however 
does not necessarily follow for proteins very 
closely related to the target itself. For a potential 
therapeutic designed to target small G proteins, 
there are many very closely related proteins that 
the molecule could encounter. 
 
The data-driven model we generated of the Cdc42-
P7 complex suggests some hypotheses as to how 
residue replacements in the second generation 
peptides have influenced binding. The key 
replacements at the Arg8 and Asp10 positions may 
allow a salt bridge to form between Asp10 and 
Lys166Cdc42, while Arg8 lies close to Tyr23 in 
Cdc42 helix α1 and could form a polar interaction 
here. The replacement of His8 and Gln10 in C1 
and P1 for charged residues in P7 therefore 
increases the affinity of P7, by imparting the 
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ability to form the ionic interaction involving 
Asp10P7 and Arg8P7.  
 
The most marked difference between P7 and 
C1/P1 is the reduced binding to RhoA by P7, 
which is likely due to Arg8 and Asp10. Tyr23Cdc42, 
which, in the model, is close to Arg8 in P7, is 
replaced by Phe in RhoA, which would remove 
any polar interaction between these sidechains. 
Lys166Cdc42, which forms a salt bridge with 
Asp10P7 in the model, is still present in RhoA, but 
Met45Cdc42, which is also close to Asp10, is 
replaced by Glu in RhoA. This could potentially 
destabilize the binding of Asp10 at this site. These 
interactions and substitutions between Rho family 
members potentially explain the specificity of P7 
for Cdc42 and Rac1 and could be used to guide 
fine-tuning of specificity, although detailed 
structural data on the Cdc42- P7 complex would 
be necessary to underpin any rational design 
campaign.  
 
Our structure of P7 also explains some important 
structural features of the peptide. Our binding data 
indicate the importance of the cyclized nature of 
the peptides in engaging their target. In fact 
cyclizing libraries were deliberately utilized in the 
initial stages of this project to exploit the utility of 
cyclic peptides as therapeutics. As it is difficult to 
introduce stable macrocycle linkages into a 
biological display strategy, the non-variant 
incorporation of cysteine residues was exploited in 
these libraries to allow disulphide formation and 
provide a useful platform to screen cyclic peptides.  
However the potential instability of a disulphide 
bond in cells was always acknowledged. 
 
Disulphide bonds are regulated inside the cell by 
an array of enzymes and redox molecules such as 
thioredoxin, glutathione and NADPH that increase 
the naturally slow turnover of disulphides (42). 
The major redox couples that govern cellular 
redox potential are not necessarily in equilibrium 
with each other and indeed the equilibria vary 
between intracellular compartments, generally 
being defined by the reduced/oxidised glutathione 
ratio (42). Endosomes have an oxidising potential 
while the cytosol is mainly reducing (43), and. it is 
thought that a disulphide could survive intact 
through endocytosis (44) but upon endosomal 
escape the peptide enters a reducing environment.  
How long the disulphide would last under these 
conditions is not easy to define as data are 
confounded by uptake and release rates from 
endosomes (45). Available data suggest that a 
disulphide bond in cyclized peptides may last in 
the extracellular environment but could start to 
come under attack from the point of interaction 
with a cell, however they are likely to pass through 
the endocytic pathway in an oxidised form. Upon 
release into the cytosol, disulphide bridged cyclic 
peptides should be quickly reduced, diminishing 
their binding affinity and proteolytic stability. 
Peptides however will be taken up and released 
into the cell as a gradual process; meaning release 
into the cytosol will be continual.  
  
In light of the possible instability of our lead 
peptides in cells, we have trialled various 
strategies to produce stable cyclized versions of 
these peptides. The replacement of the disulphide 
with a lanthionine bridge by alkali-catalysed 
desulphurization (46) rendered this linkage non-
labile in reducing environments and the resulting 
peptides retained the same binding affinity as 
disulphide linked forms in vitro and in CETSA 
lysate experiments (data not shown), suggesting 
that, with the appropriate chemistry, stable 
cyclized versions of these peptides can be 
successfully engineered if necessary. However, the 
biological data presented here was all obtained 
using disulphide linked peptides. Our data suggest 
that these disulphide linked peptides are actually 
relatively stable in a cellular environment, with 
biological effects seen up to 24 hours after 
exposure to peptides. The structure of the P7 
peptide reveals that it is remarkably rigid and it is 
possible that the highly compact nature of P7 
Inhibition of Ras-Cdc42 signalling by a cyclic peptide	
	 11	
protects the disulphide bond to some extent, so 
that it is less labile in a cellular environment than a 
more flexible peptide might be. The rigid P7 
structure contributes to its high affinity, since the 
binding loop containing Arg8 and Asp10 is pre-
formed and there will be no entropic penalty when 
it binds to the G protein. The peptide-binding site, 
determined by experimental chemical shift 
mapping, is within a pocket formed by the β2 
strand and helices α1 and α5 in Cdc42. This site is 
away from the nucletotide binding site and the 
nucleotide-sensitive switch regions of Cdc42, 
which explains the ability of P7 to bind Cdc42 
without nucleotide specificity. Nevertheless, 
peptide P7 can still compete with ACK for binding 
to Cdc42 (Figure 3) and is presumably an 
orthosteric inhibitor, given the overlap between the 
ACK and P7 binding sites. However, Cdc42 is, 
like all small GTPases, an allosteric protein 
(reviewed in (47)), and it is possible that P7 will 
disrupt binding of other proteins, such as GDIs 
and exchange factors, that do not directly engage 
with the P7 binding pocket.  
 
The model of the Cdc42-P7 complex may also 
explain the observation that Cdc42 engagement by 
P7 leads to destabilization of the small G protein 
(Figure 8C and D). This was potentially 
unexpected, given that the binding of the CRIB 
effectors is likely to stabilize both binding partners 
as two disordered regions coalesce into a more 
rigid complex (48). Other systems using CETSAs 
have reported stabilization, destabilization and no-
change with target engagement and the effect 
appears difficult to predict (49,50).	 However the 
distinct binding mode of P7, interacting with 
regions that are already structured in the free 
Cdc42 would not necessarily stabilize the protein 
and could potentially inhibit interaction with 
binding partners that confer thermal stability.	 
 
The addition of a CPP motif allowed the peptides 
access to the cell interior in both MEF and A549 
cells. The general mechanism of CPP entry has 
been a subject of some debate but appears most 
likely to be through endosomal uptake and escape 
(51). Certainly this seems to be the case with the 
peptides described here. The kinetics of cellular 
distribution appear to be different in MEFs and 
A549s, however in both cell types the effects 
observed suggest sufficient peptide delivery to the 
target to obtain measurable biological effects.  
 
Pulldown inhibition in lysates has demonstrated 
that the peptides are specific and soluble enough 
among the cell contents to bind and inhibit Cdc42-
effector interactions, but, interestingly, the 
addition of N-terminal FAM and C-terminal 9R 
considerably reduce the potency of Cdc42 
interaction inhibition. The most likely reasons for 
this approximately 10-50-fold reduction in 
potency are that the 9R motif binds non-
specifically to other moieties or causes 
aggregation in the lysate. These results suggest 
that the cellular potency of the peptides is reduced 
by this CPP motif, an effect that is likely to be 
general to peptides using a 9R CPP. No 
therapeutics have made it to clinical trials using 
such a motif and, aside from the toxicity issues 
which are confirmed in Figure 2C, this reduction 
in target specificity could be a contributory reason 
in some cases. An alternative delivery system 
therefore should dramatically improve potency in 
this case. Methods to improve delivery could 
either employ a cleavable linker or another cell 
penetration strategy.	
 
The early promise of C1 in decreasing signalling 
to STAT3 and ERK1/2 in MEFs has been 
consolidated by potent second generation peptide 
effects on proliferation and especially migration in 
the more aggressive A549 cell line. The fact that 
these peptides were selected to target the Rho-
family small-GTPases, which are known to control 
cytoskeletal structure and migration, makes it 
encouraging that the most potent effects of the 
matured peptides are on cell motility. Data 
presented here have demonstrated effective target 
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engagement in the cellular environment, however 
it is uncertain how important inhibition of off-
target small-GTPases is to overall peptide efficacy. 
P1 shows more potency than P7 in Boyden 
chamber and proliferation assays despite having a 
lower affinity for Cdc42. P1 however has 
relatively high affinity for RhoA and it may be that 
inhibition of RhoA, or indeed another related Rho 
GTPase, is important for these effects. P7 
performs best in wound healing assays, where, 
presumably, high affinity for Cdc42 is most 
efficacious.  Our data, therefore, suggest that 
simultaneous targeting of several Rho family 
GTPases could result in improved anti-oncogenic 
effects; indeed arguments for true 
polypharmacology are presently redefining drug 
discovery paradigms (52). This opens up 
interesting future studies into how inhibition by 
different peptide derivatives from C1 could tune 
various signalling pathways and phenotypic 
effects.  
 
The effect we see on ERK1/2 signalling is an 
interesting example of the type of effects we were 
hoping to see in these peptides. Traditionally 
ERK1/2 phosphorylation is monitored as a readout 
for Ras signalling. We see down regulation of 
pERK1/2. However in this case we assume that 
this is due to inhibition of the Cdc42-PAK 
complex. PAK is another CRIB effector of Cdc42 
(and indeed of Rac1), which is known to be 
involved in regulation of ERK activity as it 
regulates phosphorylation of both Raf and MEK, 
contributing to activation of the Raf-MEK-ERK 
pathway (53,54). Thus the peptides appear to 
inhibit the interaction of Cdc42 (and possibly 
other Rho-family GTPases) with multiple effectors 
due to the similarity in the effector engagement 
sites and act as blockades of Cdc42 signalling. The 
similarity in the CRIB-effector interfaces and their 
overlap with the P7 binding site (Figure 6) provide 
a rational explanation for the ability of P7 to 
inhibit multiple effector pathways. 
 
In summary, the peptides isolated in this study 
show promise as inhibitors of oncogenic 
phenotypes in Ras-driven cancers, a hugely 
important cohort of cancers that have proved 
difficult to treat to date. Their activity is dependent 
on their cyclic nature and while they appear to 
contain a relatively stable disulphide bond, which 
confers activity in cells for several hours, 
introduction of a non-labile cyclization was also 
possible without compromising activity. Other 
strategies to increase stability of the peptides using 
unnatural bonds and residues are currently under 
investigation. Utilization of a 9R CPP motif for 
experimental purposes was successful but a 9R 
control peptide did show significant toxic effects 
on cells above a threshold concentration. More 
importantly the 9R CPP, when conjugated to the 
peptides, reduced target engagement by ~10-50-
fold in cell lysate. Alternative peptide entry 
strategies are also currently under investigation 
and should dramatically improve efficacy of these 
peptides in vivo. Slight changes in the C1 peptide 
sequence were also shown to modulate specificity 
to small GTPases and change phenotypic effects 
suggesting that the target selection of these 
peptides can be adapted. A degree of 
polypharmacology is also likely to be desirable in 
future anti-cancer therapeutics and tuning 
alternative-target binding should improve 
therapeutic properties further. 	
The peptides we describe here are examples of 
peptide macrocycle technology applied to the 
highly intractable target class of small G proteins 
and represent a promising new modality for future 
therapeutics. Our data also adds to the growing 
literature demonstrating that peptides are 
establishing their place in the biologics arm of 
drug discovery. Importantly here we create early 
lead therapeutic biologics for one of the most 
urgent clinical needs in cancer presented today.  
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Experimental Procedures 
Protein preparation 
Target proteins were expressed in pGEX-2T (GE 
Healthcare) as GST fusion proteins. Constructs 
expressing the ACK and WASP GBDs, Cdc42 Δ7 
Q61L, Cdc42 Δ7, Rac1 Δ7 Q61L, RhoA Δ12 
Q63L, RalA Δ21 Q72L and RalB Δ21 Q72L 
have been previously described (55-57). Human 
K-Ras 4B (residues 1-169) was amplified by PCR 
and cloned into pGEX-6P (GE Healthcare) using 
BamHI and EcoRI sites that had been incorporated 
into the PCR primers.	 A Q61L mutation was 
introduced using QuikChange Lighting 
mutagenesis (Agilent), following manufacturer’s 
instructions.	Recombinant proteins were expressed 
in E. coli, affinity purified on glutathione agarose 
resin (Sigma-Aldrich) and cleaved (except for 
GST ACK/WASP) from GST using thrombin 
(Novagen) or C3 protease. Cleaved proteins were 
purified by gel filtration (S75 16/60, GE 
Healthcare), while GST ACK/WASP were 
purified by ion exchange as described previously 
(18,37). Nucleotide exchange reactions were 
performed for small G proteins to add the non-
hydrolysable GTP analogue, GMPPNP, or tritiated 
GTP as described previously (18). Cdc42 was 
biotinylated for use in CIS display. EZ-link Sulfo-
NHS-biotin (Thermofisher) was incubated for 30 
min at room temperature with Cdc42 at a molar 
ratio of 20:1. Reactions were performed in PBS 
according to manufacturer’s instructions and the 
protein recovered from the reaction mix using 
PD10 desalting columns (GE Healthcare). 
 
CIS display 
Three naïve library populations were created by 
mixing 10 random peptide encoding libraries 
generated from oligonucleotide primers purchased 
from Ella Biotech GMBH. The variant regions of 
these primers were built from DNA trimers 
designed to give equal amino acid frequencies 
(with the exclusion of cysteine) and optimized for 
expression in E. coli. Linear libraries comprised 
varying lengths of contiguous random amino 
acids, whilst cyclic libraries followed a sequence 
pattern of X3CXNCX3 where X denotes random 
amino acid representation (excluding Cys) and N 
was defined by the library length. The C1 
maturation library conserved the cysteine residues 
for cyclic linkage but introduced biased 
mutagenesis at all other nucleotide positions, with 
79% parental conservation and 7% incorporation 
of each non-parental nucleotide. CIS display 
construct synthesis and biopanning reactions were 
performed as previously described (19). For heat 
elutions DNA was eluted from streptavidin beads 
by heating to 75 ℃ for 10 min, whereas in 
competitive elutions, beads were incubated for 1 h 
in 100 µL PBS + 2% BSA + 50 µM ACK GBD 
and the supernatant recovered. Four rounds of 
biopanning were performed for each selection and 
for the maturation campaign, before library 
analysis by next generation sequencing using the 
MiSeq Desktop Sequencer (Illumina).	
 
Phage ELISAs 
Library DNA from selections and pHEN-1 
phagemid vector were digested with NcoI and 
NotI, ligated together and transformed into TG1 E. 
coli cells (Lucigen). Transformants were picked at 
random and 30 µL of overnight culture derived 
from individual colonies was used to seed cultures 
in 300 µL 2TY, 2% glucose, 100 µg/mL 
ampicillin, which were incubated at 37 ℃ with 
shaking to O.D.600 = 0.3. 108 pfu M13K07 helper 
phage in culture medium were added to each well 
and the cultures incubated for 1 h at 37 ℃ without 
shaking. Cells were centrifuged, the supernatant 
discarded and bacteria resuspended in 400 µL 
2TY, 100 µg/mL ampicillin, 25 µg/mL kanamycin 
per well and incubated overnight at 37 ℃ with 
shaking to allow phage expression. The 
recombinant phage were recovered in the 
supernatant after centrifugation for screening. 
 
NUNC Maxisorp plates were coated overnight 
with streptavidin (Pierce) at 250 ng per well for 
assays using biotinylated Cdc42. Assay plates for 
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specificity tests were coated directly with 500 ng 
per well, recombinant small GTPases or bovine 
serum albumin (BSA). Wells were washed in PBS 
and blocked in 1% BSA in PBS for 2 h at 20 ℃. 
The streptavidin plates were then incubated with 
biotinylated Cdc42·GMPPNP (100 ng per well for 
30 min) and the wells subsequently washed in 
PBS.	
 
In parallel the phage were blocked in PBS 
containing 1% BSA for 2 h then added to target 
coated ELISA plate and shaken for 1-2 h at room 
temperature. Plates were washed (3 X PBS-Tween 
0.1%, 2 X PBS) to remove unbound phage and 
then incubated with anti M13/HRP antibody 
conjugate (B62-FE2, Abcam: 1/5000 dilution in 
PBS containing 2% BSA). Plates were washed as 
before and TMB (eBioscience) (50 µL per well) 
added. Wells were quenched with 50 µL 0.5M 
H2SO4 after blue colouration was visible and A450 
measured using a Multiskan EX (Thermo 
Scientific). DNA from phage clones was amplified 
by PCR and sequenced (Beckman Coulter). 
 
Peptide synthesis 
Peptides with an amidated C-terminus were 
synthesized on a 10µmol scale by standard Fmoc 
solid-phase chemistry on an automated peptide 
synthesizer (MultiPep RS, Intavis, Gemany). 
Following the final Fmoc deprotection, the peptide 
N-terminus was acetylated (4% acetic anhydride, 
16% N-methylpyrrolidone (NMP) in 
dimethylfluoride (DMF) for 1 h), biotinylated (12 
equivalents biotin, 12 equivalents 
Hexafluorophosphate Benzotriazole Tetramethyl 
Uronium (HBTU), 5% N-methylmorpholine 
(NMM) in DMF overnight) or 5(6)-FAM labelled 
(5 equivalents 5(6)-FAM, 5 equivalents HBTU, 10 
equivalents NMM in DMF overnight). Resin was 
extensively washed with dichloromethane and 
methanol, and dried overnight. After deprotection 
and cleavage from the resin (TentaGel, Intavis, 
Germany) with 5% water, 5% phenol, 5% 
thioanisole, 2.5% ethanedithiol in trifluoroacetic 
acid (TFA) for 3 h, the peptides were precipitated 
in diethylether at -20 ℃. The crude peptides were 
purified by reverse-phase HPLC (Shimadzu) using 
a C18 column (50 x 250mm, SunFire, Waters) and 
a linear gradient elution 20-50% acetonitrile in 
0.1% Trifluoroacetic acid (TFA). The molecular 
masses were determined by MALDI-TOF-TOF 
mass spectrometer (AXIMA Assurance, 
Shimadzu).	 Nona-arginine linked peptides were 
purchased from Cambridge Research 
Biochemicals.	
 
 
Scintillation proximity assays (SPAs) 
30 nM GST wt-ACK GBD was immobilised on 
Protein A SPA fluoromicrospheres (Perkin Elmer) 
via an anti-GST antibody (Sigma-Aldrich). 30nM 
[3H]GTP·Cdc42 was added and the effect of 
competition measured by measuring the signal in 
the presence of increasing concentrations of the 
peptide under test. Scintillation counts were 
measured at each concentration and fitted to the 
appropriate binding isotherm as described 
previously (58). 
 
Fluorescence polarization  
Fluorescence polarization (FP) experiments were 
measured on a BMG Labtech Pherastar 
fluorimeter at 298 K with excitation 485 nm and 
emission 520 nm. Solutions were made up in black 
flat-bottom 384 well plates (Corning) to a final 
volume of 30 µL.  Anisotropy was calculated from 
polarization measurements in MARS analysis 
software and data fitted to binding isotherms in 
R(59). Direct binding data was fitted using 
equation 1, while competition data was fitted to a 
previously described equation (58). 𝑦 = 𝑆!"# + 𝑆!"# −  𝑆!"#  × !!!!! + 𝑀𝑎𝑥 −𝑁𝑆𝐵  × 𝐶    Eq 1 
 
Where y equals anisotropy; Smax equals the 
maximum binding signal; Smin, the minimum 
binding signal; C, the target concentration and 
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NSB, the non-specific binding component. For 
direct binding assays a concentration range of 
small GTPase was added to FAM-labelled 
peptides (60 nM) while in competition assays 
dilutions of unlabelled C1 peptide was added to 60 
nM FAM-C1 and 500 nM Cdc42·GMPPNP.  
 
NMR Spectroscopy and Structure Calculations. 
15N HSQC Experiments were recorded on a 
Bruker DRX500 at 298 K in 50 mM Tris-HCl pH 
7.5, 1 mM MgCl2, 5 mM DTT, 150mM NaCl, 
10% D2O. For the titration experiments 0.25, 0.5, 
1 and 1.25 equivalents of peptide were added to 
15N-labelled Cdc42 and spectra were recorded 
after each peptide addition. Overall chemical shift 
perturbations, δ, were calculated using equation 2; 
    
     Eq 2 
where δ1H and δ15N are the chemical shift changes 
for the 1H and 15N dimensions, respectively.  
2D NOESY (250 msec mixing time), TOCSY (65 
msec mixing) and DQF-COSY experiments were 
recorded on peptide P7 on a Bruker AV800 at 298 
K in 50mM sodium phosphate, pH 7, 10% D2O. 
 
All NMR data were processed using the AZARA 
package (Wayne Boucher, University of 
Cambridge) and analysed using CCPN ANALYSIS 
(60). Peptide structures were calculated using 
ARIA 1.2 (61) interfaced to CNS (62) where the 
ambiguity of the restraints was decreased during 
eight iterations. Cdc42 residues whose backbone 
amides had shifted by more than 0.043 (the 
average shift change) and which were more than 
40% solvent exposed in either of two structures 
(according to NACCESS (63)) were used as active 
residues in HADDOCK (38,39). HADDOCK was 
also run including only residues whose backbone 
amides had shifted by more than 0.090 (the 
average shift change plus 1 standard deviation). In 
all cases, residues whose peaks had shifted too far 
to be reliably assigned were included as active 
residues. The Cdc42 structures used were those 
from complexes with Par6 (PDB code 1nf3) or 
IRSp53 (PDB code 4js0), where the effector was 
removed in each case. HADDOCK was run twice 
for each set of active residues, once with each of 
these structures as a starting point. In all 
HADDOCK runs the top cluster showed the 
peptide binding in the same orientation on the 
same surface of Cdc42. The active Cdc42 residues 
were as follows (after filtering for solvent 
exposure): shifted by more than average + 1 SD, 
25, 46, 49, 164; shifted by between average and 
average +1 SD, 3, 12, 26, 62, 76, 116, 153, 167, 
177, 178; shifted too far for unambiguous 
assignment to be possible, 24, 30, 43, 48, 52, 160, 
162, 166. Passive residues were defined 
automatically by HADDOCK. Active residues for 
the peptide were defined as 8 and 10, with all 
other peptide residues being passive. 
 
Immunoblotting  
Lysates were taken from 2 X 6 cm dishes in 100 
µL lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 
1 mM β-glycerophosphate disodium salt hydrate, 
1X protease inhibitor cocktail (Mammalian, Sigma 
Aldrich), 1% Triton X-100) and centrifuged at 
17,000 g for 20 min. Cell samples were resolved 
by SDS-PAGE and immunoblotted using the 
following primary antibodies: α-Stat3 (F-2) sc-
1019, α-Stat3 (Y705) sc-7993 (Santa Cruz 
Biotechnology), α-GAPDH-HRP ab9482 
(Abcam), α-Erk1/2 9107S, α-pErk1/2 4376S (Cell 
Signaling Technology). 
 
Cellular Thermal Shift Assays (CETSA) 
For CETSA lysate experiments A549 cells were 
trypsinized, washed in PBS and resuspended in 
lysis buffer (50 mM Tris-HCl pH 8.0, 50 mM 
NaCl, 5 mM MgCl2, 1X protease inhibitor cocktail 
(Mammalian, Sigma Aldrich)) at 60,000 cells/50 
µL. Cells were lysed by three freeze-thaw cycles 
in liquid nitrogen and centrifuged. Supernatant 
was divided into 50 µL aliquots, which were 
exposed to varying concentrations of peptide or 
δ = δ1H
2 + (0.15δ
15Ν
)2
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temperatures. Cell lysates were first heated over a 
wide range of temperatures to determine the 
melting temperature of the protein under 
investigation. Samples were heated for 3 min in a 
Veriti 96-well thermal cycler (Applied 
Biosystems), then cooled for 3 min and 
centrifuged. Supernatants were analysed by 
Western blot. Lysates were then tested over a 
narrower range of temperatures below the melting 
temperature, +/- a fixed concentration of the 
peptide under test and a temperature was identified 
where a peptide effect was apparent; this 
temperature was set as the experimental 
temperature.  Finally lysates were tested at the 
experimental temperature with a range of peptide 
concentrations. For whole cell experiments 
600,000 A549 cells were seeded in 12-well culture 
plates and incubated for 3.5 h. Cells were 
trypsinized, collected and washed in PBS. Samples 
were heated for 3 min as above, 30 μL lysis buffer 
added (25 mM Tris-HCl pH 7.5, 5 mM β-
glycerophosphate, 2 mM DTT, 0.1 mM sodium 
vanadate, 10 mM MgCl2), then subjected to two 
freeze-thaw cycles before. The supernatant was 
analysed by Western blot. An experimental 
temperature was determined as above. Cells were 
then plated and incubated with a range of peptide 
concentrations for 3.5 h and analysed as above. 
 
GST pulldown assays 
Glutathione sepharose (GE Healthcare) in PBS 
was incubated for 15 min at 4 ℃ with GST-WASP 
and then washed three times in PBS, 0.1% Tween. 
25 µg GST-WASP attached to beads was 
incubated with 100 µL A549 lysate for 45 min in 
the presence of varying peptide concentrations. 
Beads were washed twice in PBS, 0.1 % Tween. 
Samples were resolved by SDS-PAGE and 
immunoblotted using an anti-Cdc42 antibody 
(610928, BD Biosciences). Western blots were 
quantified using Image J and data fitted to 
equation 3 to calculate IC50 values. % 𝑆𝑖𝑔𝑛𝑎𝑙 =100 − 100/(1 + 𝐼𝐶50/𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛          Eq 3 
Proliferation assays 
100 µL A549 cells were seeded in 96-well culture 
plates (CellStar) at 50,000 cells/mL and allowed to 
settle overnight. Peptides were dosed in 4 µL PBS 
every 24 h. After 48 h 10 µL MTT (Invitrogen, 5 
mg/mL in PBS) was added and the plates 
incubated for 2-3 h. Medium was removed and 
100 µL DMSO added to solubilize the contents. 
After 4 h the A570 absorbance was measured of 
each well in a SoftMax Pro 5 (Molecular Devices). 
 
Boyden chamber assays 
Upper chambers of Boyden chambers (BRAND) 
were seeded with 50,000 A549 cells in 100 µL 
RPMI, 0.1% FCS with 1 µM peptide doses. The 
bottom chamber was filled with RPMI, 10% FCS 
and the plates incubated for 5.5 h at 37 ℃. Cells 
and media were removed from the top chamber 
using cotton buds and the media in the bottom 
well replaced with trypsin and incubated for 10 
min at 37 ℃. The cells were removed, centrifuged 
and the cell pellets resuspended in 20 µL PBS. 
Cell suspensions were counted on the Countess 
automated cell counter (Invitrogen) and data 
analysed and plotted in R. 
 
Wound Healing Assays 
3 well microdishes (Ibidi) were seeded with 
20,000 A549 cells in 100 µL RPMI/well and 
allowed to settle overnight. Wells were dosed with 
1 µM peptide and incubated for 3 h. 0.5 mL 
medium with 1 µM peptide was added to the 
outside of the dishes and the inserts removed. 
Images were taken at various timepoints using an 
EVOS fl digital inverted microscope (AMG) at 4X 
magnification. Images were cropped to 680 by 512 
pixels (width approximately 1 mm) and scratch 
area analysed using the MiToBo package in Fiji 
(64,65). Data were processed in R. 
 
Confocal microscopy 
Cells were seeded at 50,000/mL in micro-insert μ-
dishes (Ibidi) and incubated overnight. Peptides 
were added in fresh medium and cells incubated 
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for respective timepoints. Cells were washed 4 X 
with PBS and imaged in imaging medium (H0887, 
Sigma) in a stage top heated chamber (Okolabs) at 
37 ℃. Confocal images were acquired on an 
inverted Ti-E microscope (Nikon) with a spinning-
disk (X-light Nikpow, Crest), 250 μm Lunencor 
Sprectra X LED illumination and a piezo driven Z 
stage controller (NanoScanZ) using a 100 X 1.40, 
oil objective lens (Plan Apo VC, Nikon). Images 
were collected with an EMCDD camera (Evolve 
Delta, Photometrics) with Metamorph software 
(version 7.8.2.0). 5(6) FAM samples were 
visualized using a 470/40 excitation and 525/50 
emission filters and images processed in Fiji 
(64,65). 
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Footnotes 
Abbreviations: ACK, activated Cdc42 kinase; CETSA, eellular thermal shift assays; CRIB, Cdc42/Rac 
interactive binding domain; CPP, cell penetrating peptide; DTT, dithiothreitol; FAM, carboxyfluorescein;	
FITC, fluorescein-5,6-isothiocyanate;	GAP, GTPase activating protein; GBD, G protein binding domain; 
GDP, guanosine-5'-diphosphate; GEF, guanine exchange factor; GST, glutathione-S-transferase; GTP, 
guanosine-5'-triphosphate; IPTG, isopropyl-β-D-1-thiogalactopyranoside; MEF, mouse embryonic 
fibroblast; PAK, p21 activated kinase; SPA, scintillation proximity assay; WASP, Wiskott-Aldrich 
syndrome protein; wt, wildtype; 9R, nona-arginine. 
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Table 1: Experimental Restraints and Structural Statistics a 
 
Experimental restraints 
 
Distance restraints:  
 
  Total non-degenerate   440 
 Unambiguous   408  
     Ambiguous   32 
  
 Intraresidue NOEs  170 
 Sequential NOEs  115 
 Medium & long-range NOEs   155  
  
       <SA> b   <SA> c  
 
Coordinate precision for well-ordered regions 
RMSD of all backbone atoms (Å)   0.37 ± 0.13  0.15 
RMSD of all heavy atoms  (Å)    0.69 ± 0.09   0.63 
 
RMS deviations for all residues 
from the experimental restraints: 
 NOE distances   (Å)    0.025 ± 0.0014   0.025 
      
from idealised geometry: 
 Bonds   (Å)     0.0045 ± 0.00023  0.0044 
 Angles   (˚)     0.83 ± 0.025  0.83 
 Impropers (˚)     1.30 ± 0.17  1.18 
 
Ramachandran plot analysisd 
 Core region (%)    59.5   50.0 
 Allowed region (%)    30.7   41.7 
 Generously allowed region (%)   9.0   8.3 
 Disallowed region (%)    0.7   0.0 
__________________________________________________________________________ 
 
a PDB accession code 6R28. Chemical shifts deposited at BMRB, accession code 34380. 
b <SA> represents the average RMS deviations for the ensemble of 36 structures. 
c <SA> represents values for the structure that is closest to the mean. 
d Analysed using Procheck 
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Table 2: Affinities of peptides for a panel of small G proteins measured by FP. 
 Kd (nM) ± standard deviation 
 
C1 P1 P7 
Cdc42·GDP 876.0 ± 170.0 98.4 ± 9.1 32.0 ± 4.3 
Cdc42·GMPPNP 409.0 ± 44.2 24.5 ± 8.6 14.6 ± 3.4 
Rac1·GMPPNP 355.0 ± 79.0 896.0 ± 123.0 436.0 ± 107.0 
RhoA·GMPPNP 475.0 ± 152.0 166.0 ± 52.2 ND* 
K-Ras 4B·GMPPNP 3418.0 ± 581.0 3970.0 ± 614.0 19600.0 ± 5600.0 
RalA·GMPPNP 44000.0 ± 1251.0 37040.0 ± 1340.0 ND 
 * ND (no binding) denotes data that could not be fitted to the binding isotherm 
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Figure Legends 
 
Figure 1 A: Bar charts showing the relative enrichment of peptides in each library pool and the ten most 
frequently selected sequences under each set of conditions. Sequences taken forward for further 
evaluation are highlighted in red. B: ELISA screening of phage presenting the three most enriched 
sequences. The relative absorbances from ELISA for binding against a panel of small GTPase targets as 
indicated and a BSA control are plotted as a modified box plot. n =3-4 C: Displacement of 
[3H]GTP⋅Cdc42 from GST-wt ACK GBD by C1 binding to Cdc42. Increasing concentrations of C1 or 
C1C4S, C13S were titrated into a fixed concentrations of [3H]GTP⋅Cdc42 and GST-wt ACK GBD in the 
presence or absence of 50 mM DTT, in competition SPAs. The Kd for Cdc42 binding to GST-wt ACK 
GBD was fixed to the value (30 nM) obtained for this Kd in direct SPAs. The data were fitted to an 
isotherm describing a pure competition model (58) to give an apparent Kd  (Ki) value for C1. The data and 
curve fits are displayed as a percentage of the maximal SPA signal in each assay. 
 
Figure 2 A: The affinity of C1 and FAM-C1-9R for Cdc42. The top panel shows anisotropy data for 
direct binding of 60 nM FAM-C1-9R or FAM-9R to varying concentrations of Cdc42·GMPPNP with data 
fitted to a direct binding model containing a linear non-specific-binding term. n = 3. The bottom panel 
shows the competition between 60 nM FAM-C1-9R and 500 nM Cdc42·GMPPNP with a range of 
concentrations of unmodified C1, fitted to a competition binding model to calculate binding affinity. n = 2 
B: The effect of higher concentrations of FAM-C1-9R on cells. MEFs treated with peptide or a FITC 
control for varying times are shown under 20X phase contrast. After 28 hours cells were washed twice in 
PBS and imaged by phase contrast, and fluorescence using an EVOS GFP light cube. These images are 
shown in overlay in the bottom panels. C: Entry of FAM-C1-9R into cells. Peptide at 5 different 
concentrations was applied to MEFs and the cells monitored by fluorescence confocal microscopy at a 4 
different time-points. Representative images are shown and labeled accordingly. n = 3. D: Effects of the 
peptides on signalling pathways. MEFs were incubated with FAM-C1-9R for 1 and 24 hours alongside 
untreated controls (0). Cell lines A and C expressed K-Ras G12D while B and D were wild type. Western 
blots from whole cell lysate were probed for Stat3 phospho-Tyr705, total Stat3, ERK1/2 phospho-
Thr202/204, total ERK1/2 and GAPDH. Data are representative of three independent experiments. 
 
Figure 3 A: The enrichment of replacement residues in second generation peptides after maturation by 
CIS display. At positions where the parent residue was proportionately decreased in abundance after 4 
rounds of biopanning of the cyclic maturation library, the relative enrichment of replacement residues at 
each amino acid is shown in the bar chart. Amino acids are individually coloured as shown in the key and 
labelled using one letter code where they have a greater than 2-fold enrichment. B: Second generation 
peptides. The nine selected sequences from the maturation screen are presented. Their affinities for 
Cdc42·GTP were determined by competition SPA and their Kds are given together with the standard error 
form curve fitting. n ≥ 2. C: Representative SPA data. Increasing concentrations of the ACK GBD or the 
peptides were titrated into a fixed concentrations of [3H]GTP⋅Cdc42 and GST-wt ACK GBD in 
competition SPAs. The Kd for Cdc42 binding to GST-wt ACK GBD was fixed to the value (30 nM) 
obtained for this Kd in direct SPAs. The data were fitted to an isotherm describing a pure competition 
model(58) to give an apparent Kd  (Ki) value for the peptides. The data and curve fits are displayed as a 
percentage of the maximal SPA signal in each assay. 
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Figure 4: Structural analysis of peptide P7 and its interactions with Cdc42. A. HSQC spectra of 15N-
labelled Cdc42 in its free (black) and bound (red) forms. The peaks corresponding to the free form are 
labelled with their assignment in one letter code and are connected by a blue line to the corresponding 
resonance in the bound form. Peaks that had shifted too far to be reliably assigned are labelled in blue. B.  
A surface representation of Cdc42 with those residues that experienced a larger than average shift change 
and which were more than 50% solvent exposed coloured orange. C. The family of structures of peptide 
P7 is shown in green with the disulphide bond in yellow. Side chain nitrogen atoms are in blue and 
oxygen atoms are in red (PDB accession code 6R28).  The sidechains are well defined in the structures 
with the exception of the C-terminal Arg16 and the two residues in the loop, Arg8 and Asp10, which are 
responsible for high affinity binding of this peptide. D. A backbone representation of the closest structure 
to the mean. 
 
Figure 5: A. Data-driven model of the Cdc42-peptide P7 complex generated using HADDOCK. Peptide 
P7 is shown in green with the disulphide bond in yellow and Cdc42 is blue with the nucleotide shown in a 
stick representation. Residues identified from the chemical shift mapping are depicted as coloured 
spheres: those that had shifted the most (more than average + 1 standard deviation) are coloured red, 
those that had shifted by more than average but less than average + 1 S.D are coloured yellow and those 
that had shifted too far to reliably assign are coloured orange.  B. The Cdc42-P7 model shown in the same 
orientation as in panel A in a surface representation. P7 is shown in green and Cdc42 in blue. The peptide 
binds in a Cdc42 pocket between the β2-β3 hairpin and helix α5, which is lined by residues that showed 
chemical shift changes upon peptide binding. C. A close-up of some of the interactions in the model 
indicates that Arg8, Asp10, Trp11 and Tyr15 of the peptide loop insert into the Cdc42 pocket and that salt 
bridges form between Asp10P7 and Lys166Cdc42 and Arg8P7 andTyr23Cdc42.  
 
Figure 6: The P7 binding site overlaps with the binding surface of the CRIB effectors on Cdc42. ACK, 
PAK1, WASP and the Par6 semi-CRIB all form contacts with the same pocket so that the peptide binding 
will cause steric clashes with CRIB effectors. Cdc42 is shown as a blue cartoon, peptide P7 (green) and 
the CRIB effectors (shades of pink) are shown as a semi-transparent surface overlaid on cartoons. 
 
Figure 7: The affinities of peptides FAM-C1-9R, FAM-P1-9R and FAM-P7-9R for a panel of small 
GTPases were measured by FP. The Kds (see also Table 1), determined from n ≥ 3 assays, are plotted as 
reciprocals on a radar chart to demonstrate the relative affinity of the peptides for small GTPases related 
to Cdc42. Units of 1/ Kd = µM-1.  
 
Figure 8 A. Entry of FAM-9R conjugated peptides into A549 cells.  Peptides were applied to A549 cells 
at a final concentration of 1µM and the cells monitored by confocal microscopy at a variety of time-
points. Representative images are shown and labeled accordingly. B: Inhibition of Cdc42-effector 
interactions by C1 and second generation peptides (P1 and P7). The ability of Cdc42 to interact with its 
effector WASP in A549 lysate was monitored by GST-WASP pulldown experiments. GST-WASP GBD 
immobilized on glutathione agarose beads was used to pull down endogenous Cdc42 from A549 lysates 
in the presence of various peptide concentrations. The levels of Cdc42 bound were analysed by western 
blot. Representative western blots from unconjugated C1, P1 and P7 treatments are shown in the upper 
panels. Densitometry was performed on the results from replicate experiments (n ≥ 3) and the amount of 
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Cdc42 present in pulldowns, expressed as a percentage of levels in the absence of peptides, are plotted in 
the lower panel. Data for FAM-9R conjugated peptides are also included. C1, pink; FAM-C1-9R, red: P1, 
green; P7, cyan; FAM-P7-9R, purple. Approximate IC50s were calculated from the curve fits: C1, 190 ± 
62 nM; FAM-C1-9R, 2200 ± 740 nM; P1, 18 ± 3.5 nM; P7, 1.2 ± 0.28 nM, FAM-P7-9R, 65 ± 12 nM. C: 
Target engagement by peptides. Cellular thermal stability assays (CETSA) were run in A549 lysate at 56 
℃ treated with varying concentrations of FAM-P7-9R peptide to assess target engagement. Cdc42 and 
actin (as a control) levels were quantified by western blot and a representative blot is presented showing 
destabilization of Cdc42 with increasing peptide concentration. n = 3. D: Target engagement after cell 
penetration. Whole cell CETSA experiments were run in A549 cells at 51 ℃ after 4 h incubation with 
varying concentrations of FAM-P7-9R peptide to assess target engagement after external application of 
peptide. After lysis Cdc42 and actin levels were quantified by western blot and a representative blot is 
presented showing destabilization of Cdc42 with increasing peptide concentration. n = 3. 
Figure 9 A: Peptide effects on proliferation of A549 cells. The proliferation of A549 cells was analyzed 
over 48 hours by MTT assay. Proliferation data are shown for 48 h timepoints from 6-12 replicate 
experiments at three different peptide concentrations. A570 values are shown as a proportion of the 
untreated control values and displayed as modified boxplots. Group significance testing at each dosing 
level was performed by T-test (n = 12 - 34): #, p < 0.1; *, p < 0.05; **, p<0.01. B: Peptide effects on 
migration and invasion of A549 cells. Boyden chamber assays were used to assess cell migration and 
invasion. Cells were seeded in the top chamber in 0.1% serum and migration through the membrane to 
10% serum containing media measured. Cell numbers relative to untreated control cells are shown as 
modified boxplots and a significant decrease in proliferation relative to 9R was assessed using the one-
way T-test (n = 4): #, p < 0.1; *, p < 0.05. C: Peptide effects on proliferation and migration of A549 cells. 
Scratch assays were used to measure cell proliferation and co-ordinated migration. Representative images 
over the first 24 hours of the assay are shown for each of the peptides in the left hand panels. The 
complete data set (n=3) is shown in the graph (right hand panel) with the percentage area of the scratch 
left uncovered by cells for each condition plotted at each time point, with error bars representing the 
standard error of the mean.  
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